Literature DB >> 16731605

Medians for second-trimester maternal serum markers: geographical differences and variation caused by median multiples-of-median equations.

G Vranken1, T Reynolds, J Van Nueten.   

Abstract

OBJECTIVES: To establish gestational age-specific mid-trimester normal medians for the prenatal serum markers alpha fetoprotein (AFP), human chorionic gonadotropin (HCG) and unconjugated oestriol (uE3) for a Belgian population by using the Beckman Coulter Access chemiluminiscent immunoassays; to compare these data with data obtained from other geographical regions; to propose regression coefficients for regressed medians and analyse variation induced by different regression equations; to evaluate the effect of formulas used for gestation correction on estimating risk in Down's syndrome.
DESIGN: Data derived from 862 fresh serum samples from women being screened for Down's syndrome pregnancy, composed of selected pregnancies deemed to be normal, were examined in a retrospective study. Regressed medians were calculated by using a first-degree logarithmic-linear fit of the raw data. Multiples-of-median (MoM) values estimated by using a simple logarithmic-linear equation were compared with those calculated with higher-degree polynomials chosen with a goodness-of-fit analysis. Model-specific variation was estimated and the effect on risk for Down's syndrome was evaluated.
RESULTS: Regressed medians (Y) for Access serum markers AFP (IU/ml), HCG (IU/ml) and uE3 (nmol/l) for a Belgian population can be estimated with the equation Y = 10((A+BX)) with X = decimal weeks. The best fit was obtained with a third-degree and a second-degree polynomial for AFP and uE3, respectively. Differences between the medians and among the slopes of the geographical populations were found to be significant (analysis of covariance, p<0.001).
CONCLUSIONS: Belgian marker medians versus gestational time are found to show a pattern that is similar to that in the literature. The log-linear equation is observed to give a good fit and can be suggested as a tool for calculating median MoM values for Belgian laboratories that use Access biochemical prenatal markers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731605      PMCID: PMC1860408          DOI: 10.1136/jcp.2005.034272

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

1.  Evaluation of a dimeric inhibin-A assay for assessing fetal Down syndrome: establishment, comparison, and monitoring of median concentrations for normal pregnancies.

Authors:  J Alan Erickson; Edward R Ashwood; Cynthia A Gin
Journal:  Arch Pathol Lab Med       Date:  2004-04       Impact factor: 5.534

2.  The effects of gestation dating on the calculation of patient specific risks in Down's syndrome screening.

Authors:  J Bishop; F D Dunstan; B J Nix; T M Reynolds
Journal:  Ann Clin Biochem       Date:  1995-09       Impact factor: 2.057

3.  The mathematical basis of multivariate risk screening: with special reference to screening for Down's syndrome associated pregnancy.

Authors:  T M Reynolds; M D Penney
Journal:  Ann Clin Biochem       Date:  1990-09       Impact factor: 2.057

4.  Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects.

Authors:  N J Wald; H Cuckle; J H Brock; R Peto; P E Polani; F P Woodford
Journal:  Lancet       Date:  1977-06-25       Impact factor: 79.321

5.  Assay precision of serum alpha fetoprotein in antenatal screening for neural tube defects and Down's syndrome.

Authors:  N J Wald; A K Hackshaw; L M George
Journal:  J Med Screen       Date:  2000       Impact factor: 2.136

6.  Down's syndrome risk estimates demonstrate considerable heterogeneity despite homogeneity of input.

Authors:  Tim Reynolds; Andy Ellis; Rick Jones
Journal:  Ann Clin Biochem       Date:  2004-11       Impact factor: 2.057

7.  Maternal serum triple analyte screening in pregnancy.

Authors:  J Christopher Graves; Karl E Miller; Angela D Sellers
Journal:  Am Fam Physician       Date:  2002-03-01       Impact factor: 3.292

8.  Improved parameters for risk estimation in Down's syndrome screening.

Authors:  H Cuckle
Journal:  Prenat Diagn       Date:  1995-11       Impact factor: 3.050

9.  Maternal serum alpha-fetoprotein, age, and Down syndrome risk.

Authors:  G E Palomaki; J E Haddow
Journal:  Am J Obstet Gynecol       Date:  1987-02       Impact factor: 8.661

10.  Outcome validation of the Beckman Coulter access analyzer in a second-trimester Down syndrome serum screening application.

Authors:  Andrew R MacRae; H Allen Gardner; Lynn C Allen; Sonya Tokmakejian; Nathalie Lepage
Journal:  Clin Chem       Date:  2003-01       Impact factor: 8.327

View more
  8 in total

1.  Retrospective study evaluating the performance of a first-trimester combined screening for trisomy 21 in an Italian unselected population.

Authors:  Francesco Padula; Pietro Cignini; Diana Giannarelli; Cristiana Brizzi; Claudio Coco; Laura D'Emidio; Elsa Giorgio; Maurizio Giorlandino; Lucia Mangiafico; Marialuisa Mastrandrea; Vincenzo Milite; Luisa Mobili; Cinzia Nanni; Raffaella Raffio; Cinzia Taramanni; Roberto Vigna; Alvaro Mesoraca; Domenico Bizzoco; Ivan Gabrielli; Gianluca Di Giacomo; Maria Antonietta Barone; Antonella Cima; Francesca Romana Giorlandino; Sabrina Emili; Marina Cupellaro; Claudio Giorlandino
Journal:  J Prenat Med       Date:  2014 Apr-Jun

2.  Weight correction of MoM values: which method?

Authors:  T M Reynolds; G Vranken; J Van Nueten
Journal:  J Clin Pathol       Date:  2006-04-07       Impact factor: 3.411

3.  A toolkit for the application of placental-fetal molecular biomarkers in epidemiologic studies of the fetal origins of chronic disease.

Authors:  Jennifer J Adibi; Alexander J Layden; Qing Yin; Xiaoshuang Xun; Shyamal Peddada; Rahel L Birru
Journal:  Curr Epidemiol Rep       Date:  2020-12-28

4.  Maternal serum median levels of alpha-foetoprotein, human chorionic gonadotropin & unconjugated estriol in second trimester in pregnant women from north-west India.

Authors:  Gurjit Kaur; Jyoti Srivastav; Suresh Sharma; Anju Huria; Poonam Goel; Bir Singh Chavan
Journal:  Indian J Med Res       Date:  2013       Impact factor: 2.375

5.  Triple test screening for Down syndrome: an Egyptian-tailored study.

Authors:  Hazem S Abou-Youssef; Manal M Kamal; Dina A Mehaney
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

6.  Optimization of regional median equations of prenatal screening markers for trisomy 21 in a Chinese population.

Authors:  Liangpu Xu; Hailong Huang; Lin Zheng; Deqin He; Na Lin; Linshuo Wang; Yuan Lin
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

7.  Risk stratification for early-onset fetal growth restriction in women with abnormal serum biomarkers: a retrospective cohort study.

Authors:  L Ormesher; L Warrander; Y Liu; S Thomas; L Simcox; G C S Smith; J E Myers; E D Johnstone
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

8.  Prenatal biochemical screening and long term risk of maternal cardiovascular disease: population based cohort study.

Authors:  Joel G Ray; Tianhua Huang; Wendy S Meschino; Eyal Cohen; Alison L Park
Journal:  BMJ       Date:  2018-07-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.